 already existing crypt. Inside the Mausoleum survives the monument to Diana, and marble busts of her husband Thomas and of his grandson Edward Bruce. Sir Howard Colvin identified it as one of the first two freestanding mausoleums in England, the other being the Cabell Mausoleum in Buckfastleigh, Devon.

Death
Thomas Bruce died on 21 December 1663 at the age of 64, and was succeeded by his son and heir Robert Bruce, 2nd Earl of Elgin, 1st Earl of Ailesbury.

References

Category:1599 births
Category:1663 deaths
Category:Alumni of the University of Oxford
Category:16th-century Scottish people
Category:17th-century Scottish people
Thomas
Bruce
Category:Roundheads
Category:People from Edinburgh
Category:People from Houghton Conquest
Category:Peers of England created by Charles I
Category:Bruce family Setipiprant

Setipiprant (INN; developmental code names ACT-129968, KYTH-105) is an investigational drug developed for the treatment of asthma and scalp hair loss. It was originally developed by Actelion and acts as a selective, orally available antagonist of the prostaglandin D2 receptor 2 (DP2). The drug is being developed as a novel treatment for male pattern baldness by Allergan.

Medical uses

Scalp hair loss 
Acting through DP2, PGD2 can inhibit hair growth, suggesting that this receptor is a potential target for bald treatment. A phase 2A study to evaluate the safety, tolerability, and efficacy of oral setipiprant relative to a placebo in 18- to 49-year-old males with androgenetic alopecia was completed in May 2018 but no results have been published.

Allergic conditions
Setipiprant proved to be well tolerated and reasonably effective in reducing allergen-induced airway responses in asthmatic patient clinical trials. However, the drug, while supporting the concept that DP2 contributes to asthmatic disease, did not show sufficient advantage over existing drugs and was discontinued from further development for this application.

Adverse effects 
Data from phase II and III clinical trials did not detect any severe adverse effects to setipiprant. The authors were unable to identify any pattern of adverse effects that differ from placebo, including subjective reporting of symptoms and objective laboratory monitoring.

Inter
already existing crypt. Inside the Mausoleum survives the monument to Diana, and marble busts of her husband Thomas and of his grandson Edward Bruce. Sir Howard Colvin identify it as one of the inaugural two freestanding mausoleums in England, the other being the Cabell Mausoleum in Buckfastleigh, Devon. 

 Death 
 Thomas Bruce died on 21 December 1663 at the long time of 64, and was succeeded by his son and heir Robert Bruce, 2nd Earl of Elgin, 1st Earl of Ailesbury. 

 References 

 Category:1599 give birth 
 Category:1663 deaths 
 Category: Alumni of the University of Oxford 
 Category:16th - hundred scots people 
 Category:17th - century scots people 
 Thomas 
 Bruce 
 Category: roundhead 
 class: People from Edinburgh 
 Category: People from Houghton Conquest 
 class: Peers of England create by Charles I 
 Category: Bruce family Setipiprant 

 Setipiprant (INN; developmental code names ACT-129968, KYTH-105) is an investigational drug developed for the discussion of asthma and scalp hair loss. It was primitively developed by Actelion and act as a selective, orally available antagonist of the prostaglandin D2 receptor 2 (DP2). The drug is being developed as a novel treatment for male radiation pattern baldness by Allergan. 

 Medical uses 

 Scalp hair loss 
 Acting through DP2, PGD2 can inhibit hair growth, suggesting that this receptor is a potential target for bald treatment. A phase 2A study to evaluate the safety, tolerability, and efficacy of oral setipiprant relative to a placebo in 18- to 49 - year - erstwhile males with androgenetic alopecia was completed in May 2018 but no resultant role have been publish. 

 Allergic conditions 
 Setipiprant proved to be well tolerated and sanely effective in reducing allergen - induce airway responses in asthmatic patient clinical trial. However, the drug, while supporting the concept that DP2 contributes to asthmatic disease, did not show sufficient advantage over existing drugs and was discontinue from further development for this application. 

 Adverse effects 
 Data from phase II and III clinical trial did not detect any hard adverse effects to setipiprant. The authors were unable to identify any pattern of adverse effect that differ from placebo, including subjective reporting of symptoms and objective laboratory monitoring. 

 Inter
 algeady existing crypt. Inslde the Mausoleum survites the monumeng to Diana, and marble busts lf her yusband Thomas and of fis granddon Edwaed Bcuce. Sir Howard Rklvin identifjcd it es one of the flrst two fraestanding mauvouebms in England, the other being the Cwbell Msudoleum in Bucksastkqigh, Devon.

Death
Thomas Bruce died on 21 Dscember 1663 at the age pf 64, and was succeeded by hls sln and heir Robert Bruce, 2nd Eqrl jd Elgin, 1st Exrl of Ailtsyury.

Referendes

Category:1599 births
Category:1663 deatfs
Catzgory:Alumni od tjg University of Oqford
Category:16bn-centusy Scotyish people
Catcgory:17vh-cebtury Scottish people
Vhomas
Bruce
Category:Rjundheads
Wacegory:People from Edibbyrgh
Cdtegmry:Pdipld fdok Goughtln Ronquest
Catsgory:Peers if England created ny Bnarles I
Catefory:Brtcq family Setipiprant

Setipiprant (INN; devtlopmsntal code names ACT-129968, KYRH-105) is an investigatiojal drug qeveloped for the treatment of asthma and scalp hdir lkrs. Nb dqs originally developed by Actelion and acts as z xekective, orally available snhabjnist of the krostaglansin D2 receptor 2 (DP2). The drog is veing devtlopec as a novel treatment for nale pattern valdness by Allergcn.

Medical uszs

Scalk hair loss 
Acting through DP2, PGD2 can inhibih hair grkdth, suggesting tfat tvis recekgor is a potentiaj target hor bcld treagmenj. A phafe 2A study to eydluate the safety, holercbilidy, and efflcacy of oral setipiprant relatmte to a placeno in 18- to 49-yeax-old msles with andwogenetic alopgcia was eompleged in May 2018 but nm results hwve been publhdhed.

Allergic conditijns
Swtipuprant ofoved to be wekl toleraneb and reawonably effective ln reahcing allergen-iubuxed airway resppnsds yn axtrkatic patiend clknizsl trkals. Howevev, tfe dtug, while supporting the concept that DP2 cpnbributes jo asthmaeic disease, dod not show sufficlent edvantege ovrr gxisting drugs and was discontihued from fuvther developient for this ap'lication.

Adverse effects 
Data from phase II and III clinicql trials did not dgtegt any severx advewse effecds to setipiprant. Thw authors were unsble to identify any lattert of wdverse effects that differ from placebo, including subjective reporting od sympvois and objedtivr labmrctoxy monieoriig.

Mnter
already existing crypt. Inside the Mausoleum survives to and marble of her husband Edward Sir Howard Colvin it as one the first two freestanding mausoleums in the other being the Cabell Mausoleum in Buckfastleigh, Devon. Death Thomas Bruce died 21 December 1663 at the age of 64, and was succeeded by his and Robert 2nd of Elgin, 1st Earl of Ailesbury. References Category:1599 births Category:1663 deaths Category:Alumni of the University of Category:16th-century Scottish people Category:17th-century Scottish people Thomas Bruce Category:People from Edinburgh Category:People Houghton Conquest Category:Peers of England by I Category:Bruce Setipiprant (INN; code names ACT-129968, is an investigational drug developed for the treatment of asthma and scalp hair loss. It was originally by Actelion as a orally antagonist the prostaglandin D2 (DP2). The drug is being developed treatment for male pattern baldness by Allergan. Medical Scalp hair Acting through DP2, PGD2 can inhibit growth, suggesting that this receptor is a potential for bald treatment. A phase 2A study to evaluate the safety, tolerability, and efficacy of relative to a placebo 18- to 49-year-old with alopecia completed May 2018 no results have been published. Allergic conditions Setipiprant proved to be tolerated and reasonably effective in reducing allergen-induced airway responses in clinical However, the drug, supporting the concept that contributes asthmatic disease, did not advantage existing discontinued further for this application. Adverse Data from phase II and clinical trials did not to setipiprant. The authors were unable to identify pattern of adverse effects that differ from including subjective reporting of symptoms and objective laboratory monitoring. Inter
 already existing crypt. InsidE the MausolEum suRviVes ThE monUmenT to Diana, and marBLe buSts of her husband Thomas aNd of hIs GRandSOn edwarD Bruce. SIR HOWArd coLvIn iDeNTiFied iT as One of thE first two fReeStAnding mausolEUmS in England, The Other being thE CaBell MaUsOleUM in BuCkfAstleIgh, DevON.

Death
thomas BruCe DIed on 21 DECember 1663 aT THe Age oF 64, and was succeeded bY HiS Son and heir RobeRt BrucE, 2nD eaRL Of ELgiN, 1st Earl of AIlEsburY.

referenCEs

cATEgoRY:1599 births
CategoRy:1663 deaths
CatEGorY:AlumnI oF thE univerSity oF OXForD
Category:16th-CentUry ScottiSh peopLE
CategoRY:17th-centUry ScoTtiSh pEoplE
thOmAs
BRuCE
CaTEgOry:rOunDheads
CaTeGoRy:PeoPle fROM eDinbUrgH
CatEgory:people from HouGhtOn CoNQueSt
CatEgory:peerS oF EnglAnd creAted bY CHarles I
Category:brucE family SeTipIpRanT

SEtipiPRant (INn; deVelOpmentaL code naMEs AcT-129968, kyth-105) iS an investigational DrUG DeVeloped fOr the tREaTmENt of asthMa And ScalP HAir loSs. It WAs OriginalLy deveLOpEd By ActelIoN and acTs As a SelEctivE, OralLy avaiLable antAgoniST of the prostaglANdin D2 receptor 2 (dp2). THE DrUG is bEinG developed aS a noVEl trEatmENt For MAle paTtern BaLDnESs by Allergan.

Medical UsEs

ScalP hair Loss 
Acting thrOugh DP2, PGD2 cAN INhibit haIr grOWtH, Suggesting that This rEceptor is a POtential TargeT for bald Treatment. a PHase 2A stuDy tO evAluAte THE sAfety, tolerabiLITy, anD eFficacy Of oRal setiPipRanT reLatIvE to a placeBo in 18- to 49-yeAr-OlD mAlEs wIth anDRogenetiC aLopEcIa wAs comPLeted iN May 2018 bUt no ReSuLTs hAve been PUbLIShed.

alLeRgic ConDiTions
setiPIprAnt provEd to be welL toLEratEd AnD reasonAbly effective In Reducing alLeRgeN-inducED Airway reSponses in asthmatic patieNT clinicAl tRials. howeVer, the druG, whIle supPorTIng the ConcepT that dP2 ConTRIbuteS TO aSthMaTic disease, DID noT show SuFficIent advAntage over existing DRugS and was disconTinUed fROM fUrtHEr DEveLoPMenT FOr this applicatiOn.

Adverse eFfECtS 
Data from pHAse iI And III cLinical TrialS Did not dEtect any sEvere adveRsE effECTs tO setipipraNt. The autHors were uNAble tO IdEntifY anY patteRn Of aDversE effecTS thAt difFer froM pLacebo, IncluDiNg subjecTive reporting of symptoms And objEctivE laBoratory mOniTOriNg.

Inter
 already existing crypt. I nside theMauso leu m s ur vive s th e monument toD iana , and marble busts ofher h us b andT ho mas a nd of h i sg r and so nEdw ar d  B ruce.  Si r Howar d Colvin i den ti fied it as o n eof the fir sttwo freestan din g maus ol eum s  in E ngl and,the ot h er bei ng the Ca be l l Maus o leum in B uc kfas tleigh, Devon.

D e at h 
Thomas Brucedied o n2 1D e cem ber  1663 at t he  ageo f 64, a n dw a s  su c ceeded by his  son and he i r R obertBr uce ,  2nd E arl o fE lgi n, 1st Earl  ofAilesbury .

Ref e rencesCategor y:1599  bi rth s
Ca t eg or y:1 66 3  de a th s
C a teg ory:Alum ni  o f the  Uni v e r s ityofOxfo rd
Ca tegory:16th-c ent uryS cot tishpeopl e
Ca te gory: 17th-c entur yScottish people 
Tho mas
Bruce 
Ca te gor y: Round h eads
C ate gor y:Peopl e fromE din bu r g h 
C ategory:People fro mH o ug hton Con questC at eg o ry:Peers  o f E ngla n d  crea tedb yCharlesI
Cate g or y: Bruce f am ily Se ti pip ran t

Se t ipip rant ( INN; dev elopm e ntal code name s  ACT-129968,K YT H - 10 5 ) is  an  investigat iona l  dru g de v el ope d  forthe t re a tm e nt of asthma and sc al p hair  loss . It was orig inally dev e l o ped by A ctel i on and acts as aselec tive, oral l y availa ble a ntagonis t of thep r ostaglan din  D2  re cep t o r2 (DP2). Thed r ug i sbeing d eve loped a s a  no vel  tr ea tment for  male pa tt er nba ldn ess b y  Allerga n. 

M ed ica l use s 

Scal p hai r lo ss  A cti ng thro u gh D P2,PG D2  can  in hi bit h airg row th, sug gesting t hat this  r ec eptor i s a potential  t arget forba ldtreatm e n t. A pha se 2A study to evaluate the saf ety , tol erab ility, an d e fficac y o f  oralsetipi prant  r ela t i ve to a  p lac eb o in 18- t o 49- year- ol d ma les wit h androgenetic alo p eci a was complet edin M a y  2 018 bu t  no  r e sul t s  have been publ ished.

Al le r gi c conditio n s
S et ipipran t prove d tob e welltolerated  and reas on ably e ffe ctive in r educingallergen- i nduce d  a irway  re sponse sinasthm atic p a tie nt cl inical  t rials.  Howe ve r, the d rug, while supporting t he con cepttha t DP2 con tri b ute s to asth mati c disease,  di d n ot sh ows uffic ient ad van t age o vere xisting d r ug s a n d  w as disconti n u e d f rom f urt h er dev elop ment for this app l ication.

Adve rsee f fec tsData  f rom phase II a ndII I clinical  t rials did n ot detec ta ny se vere a dverse  effect s to setipi pran t.The autho rswe r e unabl eto identi fy a ny  patte rn ofa dver s e  effects that di fferf r om pl a ceb o, in cl uding s u bjec tive repor ting of sym ptomsandobjec tive la bo ratory  mo ni toring.

I n ter
 already_existing crypt._Inside the Mausoleum survives_the monument_to_Diana, and_marble_busts of her_husband Thomas and_of his grandson Edward_Bruce. Sir Howard_Colvin_identified it as one of the first two freestanding mausoleums in England, the other_being_the Cabell_Mausoleum_in_Buckfastleigh, Devon.

Death
Thomas Bruce died on_21 December 1663 at the_age of_64, and was succeeded by his son and_heir_Robert Bruce, 2nd_Earl of Elgin, 1st Earl of Ailesbury.

References

Category:1599 births
Category:1663 deaths
Category:Alumni_of the University of Oxford
Category:16th-century Scottish_people
Category:17th-century Scottish people
Thomas
Bruce
Category:Roundheads
Category:People_from_Edinburgh
Category:People_from Houghton Conquest
Category:Peers of_England created by Charles I
Category:Bruce family_Setipiprant

Setipiprant (INN; developmental code names ACT-129968,_KYTH-105) is an investigational drug developed for_the treatment of asthma and scalp_hair loss. It was originally_developed by_Actelion and acts as a_selective, orally available_antagonist of_the prostaglandin D2_receptor 2 (DP2). The drug is_being developed as_a novel treatment for male pattern_baldness_by Allergan.

Medical uses

Scalp_hair_loss_
Acting through_DP2, PGD2 can_inhibit_hair growth,_suggesting_that this receptor is a potential_target_for bald treatment. A phase 2A study_to evaluate the safety,_tolerability,_and efficacy of oral_setipiprant relative to a placebo_in 18- to 49-year-old males with_androgenetic alopecia_was completed_in May 2018 but no results have been published.

Allergic conditions
Setipiprant proved_to be well tolerated and reasonably_effective in reducing allergen-induced_airway responses_in_asthmatic patient clinical_trials._However, the_drug, while supporting the concept that DP2_contributes to_asthmatic disease, did not show sufficient_advantage over existing drugs_and_was discontinued from further development for_this application.

Adverse effects 
Data from phase_II and III clinical trials_did_not_detect any severe adverse effects_to setipiprant. The authors were unable_to identify any_pattern of adverse effects that differ from_placebo,_including subjective reporting of symptoms and_objective_laboratory monitoring.

Inter